gdc
Pancreatic Cancer

Drugs for Pancreatic Cancer

Here are the drugs and financial support services available to patients receiving treatment for Pancreatic Cancer.

Abraxane (paclitaxel protein-bound particles; albumin-bound)

Drug company: Celgene
800-931-8691

Abraxane is a microtubule inhibitor used, in combination with Gemzar, for the treatment of patients with advanced or metastatic pancreatic cancer as first-line treatment.

Celgene offers 3 financial assistance programs for patients using Abraxane:

Celgene Commercial Co-pay Program

This program reduces the prescription copay for Abraxane to $25 or less, for patients with private insurance and an annual household income of up to $100,000.

Celgene Patient Assistance Program

Patients with no insurance, or not enough insurance to cover their medication, who meet certain financial criteria may receive Abraxane for free.

Celgene Patient Support

The program connects patients with public insurance to outside resources that may help with the cost of copays, deductibles, and insurance premiums.

Gemzar (gemcitabine)

Drug company: Eli Lilly
866-472-8663

Gemzar is a nucleoside metabolic inhibitor used as first-line treatment of patients with locally advanced (stage II or III nonresectable) or metastatic (stage IV) pancreatic cancer. Gemzar is also used in patients with pancreatic cancer who have previously received treatment with fluorouracil.

(Lilly PatientOne does not currently offer any direct financial assistance programs for Gemzar.)

Onivyde (irinotecan liposome injection)

Drug company: Ipsen
866-435-5677

Onivyde is a topoisomerase inhibitor used, in combination with fluorouracil and leucovorin, for the treatment of patients with metastatic pancreatic cancer whose disease has progressed after treatment with Gemzar.

Ipsen Cares offers 2 financial assistance programs for patients using Onivyde:

Onivyde Copay Program

Eligible patients with private insurance will pay $0 per order of Onivyde, with a maximum annual benefit of $20,000.

Ipsen Cares Patient Assistance Program

Uninsured patients who meet the income criteria may be eligible to receive Onivyde at no cost.

Tarceva (erlotinib) Tablets

Drug company: Genentech
866-422-2377

Tarceva is a kinase inhibitor used, in combination with Gemzar, for the treatment of patients with advanced-stage pancreatic cancer whose cancer has spread, grown, or cannot be surgically removed and who have not received previous chemotherapy.

Genentech offers 2 financial assistance programs for patients using Tarceva:

Genentech BioOncology Co-pay Card

The program ensures a $25 copay for privately insured patients receiving Tarceva, with up to $25,000 provided annually, and has no income requirements for participation.

Genentech Patient Foundation

This foundation provides Tarceva free of charge to uninsured or underinsured patients whose annual household income is less than $150,000. Tarceva is also provided free of charge for patients who have an annual household income of up to $75,000 for 1 person; $100,000 for 2 people; $125,000 for 3 people; $150,000 for 4 people; and up to $25,000 more for each additional person in the household.

Table. Drugs Prescribed for Pancreatic Cancer

  • Drug name (generic name)
  • Drug company
  • Indication
  • Patient support services

    Drug name (generic name)
  • Gemzar (gemcitabine)
  • Drug company
  • Eli Lilly
  • Indication
  • First-line treatment of locally advanced or metastatic pancreatic cancer

    In patients with pancreatic cancer who have received fluorouracil therapy
  • Patient support services
  • (No specific program)
    866-472-8663


    Drug name (generic name)
  • Tarceva (erlotinib) Tablets
  • Drug company
  • Genentech
  • Indication
  • Advanced-stage pancreatic cancer that has spread, grown, or cannot be surgically removed, in combination with Gemzar
  • Patient support services
  • Genentech BioOncology Co-pay Card
    855-692-6729

    Genentech Patient Foundation
    888-941-3331

Last modified: March 7, 2019

Subscribe to CONQUER: the patient voice® magazine

Receive timely cancer news & updates, patient stories, and more.

Country